Detailed price information for Marker Therapeutics Inc (MRKR-Q) from The Globe and Mail including charting and trades.
Detailed price information for Marker Therapeutics Inc (MRKR-Q) from The Globe and Mail including charting and trades.
HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the ...
Marker Therapeutics, Inc. has announced a collaboration with Cellipont Bioservices to support the cGMP manufacturing of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy, currently in ...
How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy cells? Research into an immune kill switch holds potential for controlling ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
The thymus is a specialised primary lymphoid organ that underpins the development and education of T cells. Here, immature progenitors undergo a tightly regulated series of events that not only ...